author-photo

Hans-Joachim Lueck

7

Papers

717

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (39)
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

2018 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (41)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

2017 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (282)
Surgical management of peritoneal carcinomatosis in ovarian cancer

2014
Show All
- Source
- Cite
- Save
Citations (0)
Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases

2009 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (171)
Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

2006 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (177)